Navigation Links
European researchers look for new ways to fight multi-drug-resistant bacterial infections

The Institute of Biotechnology and Biomedicine (IBB) belonging to Universitat Autnoma de Barcelona (UAB) is directing the AntiPathoGN European research project aimed at looking for new drug targets in pathogenic bacteria resistant to multiple antibiotics. To do so a consortium was created by six institutions and firms in Spain, three in Germany, one in France and one in Bulgaria. The project, which will cost approximately 7.7 million euros, will be carried out during four years. The European Union has subsidised the project with six million euros.

In the past decade bacterial resistance to antibiotics has risen significantly whereas in some cases the rise has been dramatic such as in hospital areas. It has reached such a stage that the World Health Organization considers these multi-drug-resistant microorganisms the cause of emerging infectious diseases. Currently a large amount of antibiotics available are not apt for the treatment of resistant pathogens belonging to an important group called gram-negative bacteria. On occasions, the choice narrows down to one drug such as the "last-resort" antibiotic colistin to treat infections caused by the bacteria Pseudomonas aeruginosa or Acinetobacter baumannii. At the same time, the lack of economic benefits has reduced the amount of research pharmaceutical companies dedicate to creating new antibiotics.

Given this situation, the AntiPathoGN project intends to cover the need for more knowledge of the biological processes and cell growth and division mechanisms of four of the most resistant gram-negative bacteria - Pseudomonas aeruginosa, Helicobacter pylori, Acinetobacter baumannii and Escherichia coli. These bacteria cause respiratory, digestive, urinary tract, skin and many other types of infections, and researchers aim to discover new substances which would be effective in fighting against them. The project works with a multidisciplinary approach and includes innovative contributions from the fields of microbiology, proteomics, and computational and structural biology, as well as pharmaceutics.

The AntiPathoGN project is coordinated by Xavier Daura, professor at UAB's Catalan Institute for Research and Advanced Studies (ICREA). Other participating institutes are the Institute for Biomedical Research (IRB Barcelona), the Clinical Foundation for Biomedical Research (Fundaci Clnic per a la Recerca Biomdica- FCRB), and the biotechnology firms Infociencia, Anaxomics Biotech and Microbionta.


Contact: Maria Jesus Delgado
Universitat Autonoma de Barcelona

Related medicine news :

1. Verizon Private IP Quadruples Network Capacity for Invacares European Operations
2. Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market
3. Chiltern Expands European Operations With a New Office in Belgium
4. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
5. Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors, Finds Frost & Sullivan
6. Bariatric Advantage High Protein Meal Replacement Clinical Study Presented at European Congress on Obesity
7. Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office
8. Cord Blood America Continuing European Expansion
9. EUROPACE 2009, the leading European congress on cardiac arrhythmias and pacing
10. Screening Programs to Drive European GI Videoscope Market Despite Economic Downturn, According to Millennium Research Group
11. Impliant Granted Two New U.S. Patents and Successfully Defends European Patent Opposition Case
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: